UBS Sticks to Olpasiran Despite Novartis Miss

UBS analysts are still optimistic about Amgen's Olpasiran despite Novartis missing its expectations. The analysts believe that even though Novartis did not meet its target, Olpasiran may still show heart-risk reduction benefits.

The analysts pointed out that a recent study showed that Novartis' Apabetinib had some issues with heart risk, but they think Amgen's drug might be different. They expect Amgen to provide more information about the potential benefits of Olpasiran in reducing heart risks.